RxDoctor Payments Data

Yousuf Khalifa, MD

Ophthalmology · Rochester, NYNPI 1104907963

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $32,650 of the $49,576 with a category attached, or 65.9%. 6 manufacturers reported payments, led by Carl Zeiss Meditec, Inc. at 39.9% of the total. 2025 is the largest year on record at $18,503, 2.5 times the $7,518 reported in 2019. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$49,576in general payments, 2019–2025

Across 39 payments — averaging $1271.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$20K
  • Glaukos Corporation$10K
  • Carl Zeiss Meditec USA, Inc.$8K
  • Carl Zeiss Meditec Cataract Technology Inc.$6K
  • Alcon$5K
  • Johnson & Johnson Surgical Vision, Inc.$178

What the payments were for

  • Consulting fees$32,65066%
  • Speaking & faculty fees$6,80014%
  • Travel & lodging$8,70018%
  • Food & beverage$1,4263%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,576 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York →

Medicare billing

Part B allowed, 2024
$93,788
Medicare patients
195
Services billed
412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine15$17,010
Prednisolone Acetate214$9,687
Cyclosporine23$5,609
TobradexTobramycin/Dexamethasone17$5,092
Travoprost12$2,420
Tobramycin-DexamethasoneTobramycin/Dexamethasone43$2,033
Brimonidine Tartrate57$1,944
MoxifloxacinMoxifloxacin Hcl80$1,479
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat45$928
Atropine Sulfate17$831
Ketorolac Tromethamine16$549
Latanoprost43$401
Dorzolamide Hcl17$285
ErythromycinErythromycin Base14$128
Timolol Maleate12$113

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Rochester

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →